Plosaracetam
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Plosaracetam
- Molecular weight
- 330.7
- Structure (SMILES)
- O=C1C[C@H](c2cc(F)c(F)c(F)c2)CN1Cn1ncnc1Cl
- abbv 552
- ABBV-552
- abbv552
- ABBV552
- plosaracetam
- Plosaracetam
- plosaracetam [INN]
- PLOSARACETAM [USAN]
- plosaracetam inn
- plosaracetam usan
- sdi 118
- Sdi-118
- SDI-118
- sdi118
- SDI118
- CAS registry numbers
- 1651179-19-9
- ChEMBL ID
- CHEMBL5314929
- InChIKey
- GPGBFZCJDZALPN-QMMMGPOBSA-N
- PubChem compound IDs
- 90467376
- FDA ingredient codes (UNII)
- W3LYF2KQ6F
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -racetam
- Condition
- Cognitive Dysfunction
- Highest recorded phase
- 1
- Condition identifier
- HP:0001268
- Subject identifier
- D060825
- Condition
- Cognitive Dysfunction
- Highest recorded phase
- 1
- Condition identifier
- HP:0100543
- Subject identifier
- D060825
- Condition
- Depressive Disorder
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003866
- Condition identifier
- HP_0001268
- Highest recorded phase
- 1
- Condition identifier
- HP_0100543
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002050
- Highest recorded phase
- 1
- NCT05199142
- NCT05212116
- NCT05486195
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 0
- Polar surface area
- 51.02
- Calculated partition coefficient (ALogP)
- 2.32
- Calculated partition coefficient (XLogP)
- 2.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 22
- Molecular formula
- C13H10ClF3N4O
- Monoisotopic mass
- 330.0495231
- Natural product
- No
Related records
Trials (6)
- A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect
- A Study of SDI-118 in Participants in Remission From Depression
- A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants
- A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration
- A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline
- Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
In development for (1)
- Depressive disorder Phase 1